Stop bugging me! - Antimicrobial peptides
Addressing concerns regarding super-resistant diseases which even the strongest medicines cannot touch, this peptide-packed technology is a remedy for the post-antibiotic age.
Health and BiotechSoftware
On-the-move support for schizophrenia - ACTISSIST
ACTISSIST is a new app developed at The University of Manchester to provide therapy on-the-move for those with severe mental illnesses such as schizophrenia.
Targeted tumour treatment
Current clinical solutions are not as effective as they could be, with certain cancers and tumours evading treatment. This unmet need is being met with a Hypoxia-beating new drug.
The cellular level – eNAMPT stimulation
A build-up of Nicotinamide Adenine Dinucleotide (NAD) in the body can result in the onset of various diseases and poor health outcomes. The University of Manchester have developed a new series of small molecule compounds, specifically designed to stimulate eNAMPT dimerization and have demonstrated these have potent activity leading to a corrective effect in in vitro and in vivo phenotypic models of diabetes. These could also have benefits in the treatment of a number of other diseases.